Imagion Biosystems announces positive results of its clinical trial data

Imagion Biosystems (ASX: IBX) released this week the results of an independent review of their clinical trial data, which confirms that the company’s targeted imaging agent is safe and detectable by MRI machines. The company also announced it has dosed 9 patients in its Phase 1 HER2 breast cancer study still open for enrollment in four sites across Australia.

Guided by the clinical results, Imagion has decided to prioritize the development of its targeted nanoparticles in conjuncture with the existing MRI technology, as opposed to IBX’s proprietary MRX machines. With this shift in strategy, the company hopes to eliminate the near-term expense and risks associated with developing and introducing a new type of detection technology.

The company held a webinar yesterday to discuss the announcement with shareholders. The recording can be viewed here.

Sharing the full announcement with you to see if we can get an inclusion in WI’s next newsletter. It would be great to include the link to the recording in the company blurb to drive traffic to the site.

Connect with the company and learn more about Imagion Biosystems by accessing their deal room here.